TITLE

FDA approves first stem-cell therapy

AUTHOR(S)
Traynor, Kate
PUB. DATE
December 2011
SOURCE
American Journal of Health-System Pharmacy;12/15/2011, Vol. 68 Issue 24, p2316
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports that the FDA has approved New York Blood Center's allogeneic cord-blood product, Hemacord, the first U.S.-licensed hematopoietic progenitor cell therapy. It also discusses a successful transplantation procedure using Hemacord which is indicated for patients with inherited, acquired, or myeloablative-treatment-related diseases. Also highlighted are details pertaining to the risk involved in treatment with Hemacord and recommendations related to its administration.
ACCESSION #
70534623

 

Related Articles

  • Gentium Announces NDA Submission for Defibrotide.  // Worldwide Biotech;Aug2011, Vol. 23 Issue 8, p2 

    The article reports on a new drug application (NDA) submitted by Gentium SpA to the U.S. Food and Drug Administration (FDA) for Defibrotide for the treatment of hepatic veno-occlusive disease (VOD) in patients undergoing hematopoietic stem-cell transplantation (HSCT). The drug has allegedly been...

  • Diabetic Stem-Cell �Mobilopathy�. DiPersio, John F. // New England Journal of Medicine;12/29/2011, Vol. 365 Issue 26, p2536 

    The article discusses hematopoietic stem-cell (HSC) transplantation as the primary curative treatment for hematologic cancer patients. It says that the U.S. Food and Drug Administration approved the granulocyte colony-stimulating factor (G-CSF) and granulocyte macrophage colony-stimulating...

  • Industry Pipeline.  // Ocular Surgery News;2/25/2011, Vol. 29 Issue 4, p30 

    The article offers news briefs related to pharmaceutical industry in the U.S. including Advanced Cell Technology Inc.'s MA09-hRPE drug which was granted an orphan drug designation by the Food and Drug Administration (FDA), FDA's approval of the Zymaxid anti-infective drug from Allergan Inc., and...

  • America Stem Cell, Inc. Receives Orphan Drug Designation for ASC-101; Novel Enabling Technology to Enhance Stem Cell Treatments for Cancer Patients.  // Biomedical Market Newsletter;4/30/2011, p31 

    The article reports that America Stem Cell Inc. has received Orphan Drug Designation to its ASC-101from the U.S. Food and Drug Administration (FDA). It mentions that the drug aims to improve homing to bone marrow in patients receiving hematopoietic stem cell transplantation. It affirms that the...

  • Outcomes of processing of bone marrow harvests for hematopoietic stem cell transplantation in pediatric patients utilizing a novel red blood cell sedimentation kit. Akel, Salem; Murray, Christianna; Ferguson, William; Babic, Aleksandar // Transfusion;Jul2019, Vol. 59 Issue 7, p2375 

    Background: Bone marrow (BM) grafts are often subject to manipulation to minimize infusion volume, to deplete red blood cells (RBCs), to deplete plasma, and/or to achieve optimal concentration of nucleated cells (NCs) for freezing. Here, we report results of processing and infusion...

  • FDA proposes new drug guides for consumers.  // HealthFacts;Oct95, Vol. 20 Issue 197, p2 

    Reports that the Food and Drug Administration (FDA) is proposing a new standard for drug guides for consumers. Flaws of the plan as including inability of the FDA to meet their own standards; Medication guide for the antibiotic Ceclor as FDA's prototype.

  • Recent changes to FDA-approved labeling.  // American Journal of Health-System Pharmacy;3/15/2003, Vol. 60 Issue 6, p544 

    Focuses on the changes made in the labeling approved by the U.S. Food & Drug Administration. Changes made in the brand of Estradiol; Benefits of Paroxetine hydrochloride; Warning added to the Sirolimus oral solution and tablets.

  • Standardized over-the-counter labels are not all-over-the-map. Greenberg, Eric F. // Packaging Digest;Jun2002, Vol. 39 Issue 6, p30 

    Focuses on the standardization for the labels of over-the-counter (OTC) drugs in the U.S. Features of an OTC label described by the U.S. Food and Drugs Administration (FDA); Graphics and formatting specifications to be used for the drug label; Changes in the product packages to meet the design...

  • Labeling changed on Prezista.  // AIDS Alert;Mar2010, Vol. 25 Issue 3, p34 

    The article informs that the Food and Drug Administration (FDA) in the U.S. has approved revisions to the drug darunavir product labeling to include the 96 week data from two clinical trials.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics